Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Therachon logo — Life-Transforming Therapies - Developing novel therapeutics...

Therachon

Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions

Founded 2014 Switzerland Switzerland 1 employees Series B Total: $100.00M Biotechnology, Health and Wellness

General Information

Company Name Therachon
Founded Year 2014
Location Switzerland Switzerland
Employees 1
Industries Biotechnology, Health and Wellness
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Therachon. To contact Therachon, visit therachon.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Therachon compare?

A PDF of Therachon and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Therachon soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Therachon

Therachon, a Switzerland-based biopharmaceutical company, is dedicated to developing and commercializing innovative therapies for severe rare conditions with significant unmet medical needs. The company's lead product candidate, apraglutide, holds promise as a potentially best-in-class synthetic peptide analog of glucagon-like peptide-2 (GLP-2) and is currently undergoing evaluation in two Phase 2 clinical trials for the treatment of short bowel syndrome (SBS). SBS is a malabsorption disorder resulting from the loss of functional small intestine. Therachon's second product candidate, TA-46, targets achondroplasia, a rare genetic condition and the most common form of short-limbed dwarfism in humans and has completed a Phase 1 clinical trial. The company's efforts are aligned with addressing gastrointestinal and musculoskeletal disorders, demonstrating a commitment to tackling challenging medical conditions. With a founding year of 2014, Therachon's recent progress includes a substantial $60.00M Series B investment in August 2018, which attracted notable investors such as Novo Holdings, Bpifrance, OrbiMed, Versant Ventures, Cowen Digital, Tekla Capital, Inserm Transfert Initiative, and Pfizer Venture Investments. In summary, Therachon is a company making significant strides in the field of biotechnology, with a strong focus on rare conditions and a promising pipeline. The recent Series B investment reflects the confidence of reputable investors in the company's potential and its ability to bring life-transforming therapies to market.

Business keywords: biopharmaceutical company, rare genetic diseases, clinical stage, therapeutics, novel treatments, malabsorption disorder, glucagon-like peptide-2, Phase 2 clinical trials, achondroplasia, short-limbed dwarfism, global biotechnology, protein therapy, Switzerland, France

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $60.00M 8
Novo Holdings Bpifrance OrbiMed
Novo Holdings, Bpifrance +6
09 Aug 2018
Series A $5.00M 2
OrbiMed Inserm Transfert Initiative
OrbiMed, Inserm Transfert Initiative
06 Jan 2017
Series A $35.00M -
30 Sep 2015

Therachon Alternatives & Competitors

View All Alternatives
Therachon vs
Microbion Corporation
Microbion Corporation United States

Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic, and serio...

Venture round
16 employees
Biotechnology, Health Care
Therachon vs
Rezolute, Inc.
Rezolute, Inc. United States

Rezolute is developing transformative therapeutics for rare and metabolic diseases.

Post-IPO Equity
66 employees
Biotechnology, Health Care
Therachon vs
Wilson Therapeutics
Wilson Therapeutics

Innovative pathways to treat rare conditions and enhance patient lives

Post-IPO Equity
Biotechnology, Health Care
Also compare with: Therachon vs Larimar Therapeutics Inc. Larimar Therapeutics Inc. Therachon vs Zevra Therapeutics Zevra Therapeutics View all alternatives

FAQ About Therachon

Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions
Therachon was founded in 2014.
Therachon is headquartered in Switzerland.
Therachon operates in Biotechnology and Health and Wellness. Its work centres on biopharmaceutical company, rare genetic diseases, clinical stage and therapeutics.
Therachon has approximately 1 employees.
Therachon has completed 3 funding rounds, raising a total of $100.00M. The latest funding stage is Series B.
Top alternatives and competitors to Therachon include Microbion Corporation, Rezolute, Inc., Wilson Therapeutics, Avalo Therapeutics, Applied Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Therachon and Microbion Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Therachon, https://bouncewatch.com/company/therachon, updated 16 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout